Modification of the fatty acid-induced thrombocytopenia by anticoagulants and compounds which inhibit in vitro platelet aggregation.
D000227:Adenine Nucleotides; D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D001728:Dicumarol / Q000627:therapeutic use; D005227:Fatty Acids; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006496:Heparinoids / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D008297:Male; D010653:Phenylbutazone / Q000627:therapeutic use; D011817:Rabbits; D012702:Serotonin Antagonists; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000227:Adenine Nucleotides; D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D005227:Fatty Acids; D006496:Heparinoids; D006634:Histamine H1 Antagonists; D012702:Serotonin Antagonists; D014149:Tranquilizing Agents; D001728:Dicumarol; D000255:Adenosine Triphosphate; D006493:Heparin; D010653:Phenylbutazone